Findings

What do systematic reviews say?

97 questions · 97 findings · 17 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 21 · 21.6%GRADE not reported 4 · 4.1%Very low 33 · 34%Low 19 · 19.6%Moderate 17 · 17.5%High 3 · 3.1%

Gabapentin vs placebo

At least 30% reduction in pain · adults with fibromyalgia

1 finding from 1 review

Gabapentin for fibromyalgia pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Very low

Gabapentin vs placebo

At least 50% reduction in pain · adults with fibromyalgia

1 finding from 1 review

Gabapentin for fibromyalgia pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Gabapentin vs placebo

PGIC ‐ any category of "better" at 12 weeks · adults with fibromyalgia

1 finding from 1 review

Gabapentin for fibromyalgia pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Very low

Gabapentin vs placebo

Withdrawals due to adverse events · adults with fibromyalgia

1 finding from 1 review

Gabapentin for fibromyalgia pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Very low

Gabapentin vs placebo

Serious adverse events · adults with fibromyalgia

1 finding from 1 review

Gabapentin for fibromyalgia pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Very low

Gabapentin vs placebo

Deaths · adults with fibromyalgia

1 finding from 1 review

Gabapentin for fibromyalgia pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Very low

Anticonvulsants (gabapentin 300 mg/day) vs placebo

Adverse effects: drowsiness (gabapentin alone) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether anticonvulsants (gabapentin 300 mg/day) changes adverse effects: drowsiness (gabapentin alone) compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
short-term (up to 3 months)
RR 31.95 [1.84, 553.64]
1 study · 80 participants
Very low

Gabapentin vs cetirizine (antihistamine)

Change in burn‐related pruritus (VAS) ( · people with postburn pruritus

Gabapentin showed no clear difference in change in burn‐related pruritus (VAS) ( compared with cetirizine (antihistamine) (low certainty).

1 finding from 1 review

Interventions for postburn pruritus 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Gabapentin vs cetirizine (antihistamine)

Somnolence · people with postburn pruritus

Gabapentin may leads to lower adverse events (somnolence) compared with cetirizine (antihistamine) (low certainty).

1 finding from 1 review

Interventions for postburn pruritus 2024 · Cochrane Headline outcomes only
RR 0.02 [0, 0.38]
1 study · 40 participants
Low

Gabapentin vs cetirizine (antihistamine)

Pain · people with postburn pruritus

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for postburn pruritus 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

Severity of PTSD symptoms ‐ Clinician‐rated · adults (aged 18 and older) exposed to a traumatic event

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Gabapentin vs placebo

Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

PTSD rate at 3 months · adults (aged 18 and older) exposed to a traumatic event

It is very uncertain whether gabapentin changes PTSD rate at 3 months compared with placebo (very low certainty).

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.8 [0.18, 3.59]
1 study · 26 participants
Very low

Gabapentin vs placebo

Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs amitriptyline

Participant‐reported pain relief of 30% or greater · children and adolescents with chronic non‐cancer pain

The review found no eligible studies for this question.

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs amitriptyline

Participant‐reported pain relief of 50% or greater · children and adolescents with chronic non‐cancer pain

The review found no eligible studies for this question.

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs amitriptyline

Patient Global Impression of Change much or very much improved · children and adolescents with chronic non‐cancer pain

The review found no eligible studies for this question.

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs amitriptyline

Any adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low

Gabapentin vs amitriptyline

Serious adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low